ERBB2 and cancer: Strategies combining with trastuzumab with chemotherapeutic agents have shown better therapeutic outcomes than chemotherapy alone in HER2-positive cancers, resulting in higher pathological complete response rates and lower risks of disease relapse and death [30,31].